HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Generated $0.4 million in revenue from nPulse Vybrance capital and disposables. Presented data at NASIT demonstrating 74% benign thyroid nodule volume reduction rate with no regrowth at 15-22 months ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an ...
Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System “Electroanatomical mapping results for the first 24 patients treated with the nPulse ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...
Hosted on MSN
Pulse Biosciences targets Q1 completion of PRECISE-BTN study enrollment as clinical adoption grows
CEO Paul LaViolette highlighted significant momentum across Pulse Biosciences’ three market development programs, emphasizing early adoption and progress in clinical trials. LaViolette stated, "We are ...
Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results